znf410 Search Results


znf410  (Proteintech)
93
Proteintech znf410
Summary of pomalidomide- and lenalidomide-derivative compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of <t>ZNF410,</t> which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.
Znf410, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/znf410/ZNF410+Antibody/bio_rxiv__64898__2026__02__06__704516-299-39-40
Average 93 stars, based on 1 article reviews
znf410 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
znf410 cdna (clone id: ohu10535)  (GenScript corporation)
90
GenScript corporation znf410 cdna (clone id: ohu10535)
(A) RNA-seq analysis of HUDEP-2 cells transduced with <t>ZNF410</t> sgRNA#1. Infected cells were sorted and differentiated for 7 days. Plotted is the average fold change in mRNA levels of two biological replicates. Genes encoding NuRD complex subunits and γ-globin (HBG) are indicated. Fragments per kilobase of transcript per million (FPKM) mapped reads were used to calculate fold change. NT, non-targeting. The x axis indicates the rank numbers of the genes.
Znf410 Cdna (Clone Id: Ohu10535), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/znf410/znf410+cdna++clone+id++ohu10535+/pmc08556680-680-1-14
Average 90 stars, based on 1 article reviews
znf410 cdna (clone id: ohu10535) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
znf410 antibody hrp  (Abbexa)
N/A
ZNF410 Antibody HRP is a Rabbit Polyclonal against ZNF410 conjugated to HRP
   Buy from Supplier
znf410 polyclonal antibody  (Elabscience Biotechnology)
N/A
ZNF410 is the transcription factor that activates transcription of matrix-remodeling genes such as MMP1 during fibroblast senescence.
   Buy from Supplier
znf410 antibody  (ProSci Incorporated)
N/A
ZNF410 Antibody raised in Rabbit validated in WB in Human.
   Buy from Supplier
znf410 antibody  (Novus Biologicals)
N/A
The ZNF410 Antibody from Novus is a ZNF410 antibody to ZNF410. This antibody reacts with Human. The ZNF410 antibody has been validated for the following applications: Western Blot.
   Buy from Supplier
recombinant human znf410 protein  (Novus Biologicals)
N/A
The Recombinant Human ZNF410 Protein has been validated for the following applications Western Blot ELISA Protein Array Immunoaffinity Purification
   Buy from Supplier
znf410 human gene knockout kit  (OriGene)
N/A
ZNF410 KN2 0 Human gene knockout kit via CRISPR non homology mediated
   Buy from Supplier
znf410 nm 021188 human tagged orf clone  (OriGene)
N/A
ZNF410 GFP tagged Human zinc finger protein 410 ZNF410
   Buy from Supplier
znf410 human sirna oligo duplex  (OriGene)
N/A
ZNF410 Human 3 unique 27mer siRNA duplexes 2 nmol each
   Buy from Supplier
znf410 nm 021188 human tagged orf clone lentiviral particle  (OriGene)
N/A
Lenti ORF particles ZNF410 Myc DDK tagged Human zinc finger protein 410 ZNF410 200ul 10 7 TU mL
   Buy from Supplier

Image Search Results


Summary of pomalidomide- and lenalidomide-derivative compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.

Journal: bioRxiv

Article Title: Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells

doi: 10.64898/2026.02.06.704516

Figure Lengend Snippet: Summary of pomalidomide- and lenalidomide-derivative compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.

Article Snippet: Primary antibodies included DNMT1 (Cell Signaling Technology - CST #5032), H3K9me2 (CST #4658), H3K27me3 (CST #9733s), H3 (CST #14269), EED (CST #51673), GAPDH (CST #5174), β-globin (37-8) (Santa Cruz #21757), γ-globin (51-7) (Santa Cruz #21756), BCL11A (Novus Biologicals #NB600-261), ZNF410 (Proteintech #14529-1-AP), IKZF1 (CST #14859) and actin (Sigma-Aldrich #A2228).

Techniques: Flow Cytometry, Positive Control, Western Blot, Mass Spectrometry

Models of BCL11A regulation across three complementary layers. ( A ) The ZF0-mediated oligomerization assembles different BCL11A splice variants (depicted as different lengths), all of which contain ZF0, enabling BCL11A to form high-order polymers. ( B ) The EED inhibitor FTX6058 reduces BCL11A dosage mainly through LIN28B, which modulates BCL11A translation. ( C ) Sequence alignment of known pomalidomide degrons (IKZF1 and ZFP91) and dWIZ-2 target (WIZ), and the corresponding ZF units of ZNF410 and BCL11A. Zinc-coordinating residues are colored blue, and residues critical for the selectivity of pomalidomide- or lenalidomide-derived degraders are shown in red. ( D ) The pomalidomide-derived compound 1075 induces degradation of ZFP91 and IKZF1, reshaping the regulatory network contributing to HbF induction.

Journal: bioRxiv

Article Title: Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells

doi: 10.64898/2026.02.06.704516

Figure Lengend Snippet: Models of BCL11A regulation across three complementary layers. ( A ) The ZF0-mediated oligomerization assembles different BCL11A splice variants (depicted as different lengths), all of which contain ZF0, enabling BCL11A to form high-order polymers. ( B ) The EED inhibitor FTX6058 reduces BCL11A dosage mainly through LIN28B, which modulates BCL11A translation. ( C ) Sequence alignment of known pomalidomide degrons (IKZF1 and ZFP91) and dWIZ-2 target (WIZ), and the corresponding ZF units of ZNF410 and BCL11A. Zinc-coordinating residues are colored blue, and residues critical for the selectivity of pomalidomide- or lenalidomide-derived degraders are shown in red. ( D ) The pomalidomide-derived compound 1075 induces degradation of ZFP91 and IKZF1, reshaping the regulatory network contributing to HbF induction.

Article Snippet: Primary antibodies included DNMT1 (Cell Signaling Technology - CST #5032), H3K9me2 (CST #4658), H3K27me3 (CST #9733s), H3 (CST #14269), EED (CST #51673), GAPDH (CST #5174), β-globin (37-8) (Santa Cruz #21757), γ-globin (51-7) (Santa Cruz #21756), BCL11A (Novus Biologicals #NB600-261), ZNF410 (Proteintech #14529-1-AP), IKZF1 (CST #14859) and actin (Sigma-Aldrich #A2228).

Techniques: Sequencing, Derivative Assay

(A) RNA-seq analysis of HUDEP-2 cells transduced with ZNF410 sgRNA#1. Infected cells were sorted and differentiated for 7 days. Plotted is the average fold change in mRNA levels of two biological replicates. Genes encoding NuRD complex subunits and γ-globin (HBG) are indicated. Fragments per kilobase of transcript per million (FPKM) mapped reads were used to calculate fold change. NT, non-targeting. The x axis indicates the rank numbers of the genes.

Journal: Molecular cell

Article Title: ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

doi: 10.1016/j.molcel.2020.11.006

Figure Lengend Snippet: (A) RNA-seq analysis of HUDEP-2 cells transduced with ZNF410 sgRNA#1. Infected cells were sorted and differentiated for 7 days. Plotted is the average fold change in mRNA levels of two biological replicates. Genes encoding NuRD complex subunits and γ-globin (HBG) are indicated. Fragments per kilobase of transcript per million (FPKM) mapped reads were used to calculate fold change. NT, non-targeting. The x axis indicates the rank numbers of the genes.

Article Snippet: The ZNF410 cDNA (clone ID: OHu10535), CHD4 cDNA (clone ID: OHu28780) were purchased from GenScript and were sub-cloned into a lentiviral vector pSDM101-IRES-GFP (from Dr. Patrick Grant lab).

Techniques: RNA Sequencing, Transduction, Infection

(A) ChIP-seq profiles of endogenous ZNF410, HA-ZNF410, and H3K27ac. The CHD4 promoter and enhancer are highlighted in orange. ZNF410 binding motifs are denoted by vertical black lines at the bottom. The 8 peak-associated genes are shown below the tracks. ZNF410 knockout (KO) cells and cells transduced with empty vector serve as negative controls. Pro, proximal; dis, distal; HA-ZNF410, N-terminal HA-tagged ZNF410; HA, hemagglutinin.

Journal: Molecular cell

Article Title: ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

doi: 10.1016/j.molcel.2020.11.006

Figure Lengend Snippet: (A) ChIP-seq profiles of endogenous ZNF410, HA-ZNF410, and H3K27ac. The CHD4 promoter and enhancer are highlighted in orange. ZNF410 binding motifs are denoted by vertical black lines at the bottom. The 8 peak-associated genes are shown below the tracks. ZNF410 knockout (KO) cells and cells transduced with empty vector serve as negative controls. Pro, proximal; dis, distal; HA-ZNF410, N-terminal HA-tagged ZNF410; HA, hemagglutinin.

Article Snippet: The ZNF410 cDNA (clone ID: OHu10535), CHD4 cDNA (clone ID: OHu28780) were purchased from GenScript and were sub-cloned into a lentiviral vector pSDM101-IRES-GFP (from Dr. Patrick Grant lab).

Techniques: ChIP-sequencing, Binding Assay, Knock-Out, Transduction, Plasmid Preparation

(A) Schematic of human ZNF410. ZNF410 contains 478 amino acids, with five C2H2-type zinc fingers (ZFs) between amino acids 217 and 366.

Journal: Molecular cell

Article Title: ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

doi: 10.1016/j.molcel.2020.11.006

Figure Lengend Snippet: (A) Schematic of human ZNF410. ZNF410 contains 478 amino acids, with five C2H2-type zinc fingers (ZFs) between amino acids 217 and 366.

Article Snippet: The ZNF410 cDNA (clone ID: OHu10535), CHD4 cDNA (clone ID: OHu28780) were purchased from GenScript and were sub-cloned into a lentiviral vector pSDM101-IRES-GFP (from Dr. Patrick Grant lab).

Techniques: Zinc-Fingers

KEY RESOURCES TABLE

Journal: Molecular cell

Article Title: ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

doi: 10.1016/j.molcel.2020.11.006

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: The ZNF410 cDNA (clone ID: OHu10535), CHD4 cDNA (clone ID: OHu28780) were purchased from GenScript and were sub-cloned into a lentiviral vector pSDM101-IRES-GFP (from Dr. Patrick Grant lab).

Techniques: Virus, Recombinant, Reverse Transcription, SYBR Green Assay, Gel Extraction, Purification, Sequencing, Control, Software